MedTrace Logo

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

NCT02490904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2023-06-18

No results posted yet for this study

Summary

Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.

Conditions

  • End-stage Renal Disease

Interventions

DRUG

Eplerenone

Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours

DRUG

Placebo

Double-blinded Placebo administered for 4 days at 25mg every 12 hours

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Frédéric JAISSER, MD · CHRU de Nancy

  • Sophie GIRERD, MD · CHRU de NANCY

  • Nicolas GIRERD, MD, PhD · CHRU de Nancy

  • Luc FRIMAT, MD, PhD · CHRU de Nancy

  • Patrick ROSSIGNOL, MD, PhD · CHRU de Nancy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-19
Primary Completion
2021-11-09
Completion
2031-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490904 on ClinicalTrials.gov